IDgenetix
Commercial- Indications
- Major depressive disorder, Schizophrenia, Bipolar disorder, Anxiety disorders, Panic disorder, Obsessive-compulsive personality disorder, Post-traumatic stress disorder, Attention deficit hyperactivity disorder
Company intelligence / Profile preview
AltheaDx specializes in commercial-stage molecular diagnostic tests focused on pharmacogenomics. Its flagship product, IDgenetix®, provides genetic insights to guide medication selection for depression, anxiety, cardiovascular disease, pain management, and neuropsychiatric disorders. A published randomized controlled trial demonstrated that using IDgenetix prior to prescribing improved outcomes over standard of care. The test has received Medicare reimbursement since late 2020. The company maintains CAP-accredited/CLIA-certified labs in San Diego and was acquired by Castle Biosciences in April 2022.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AltheaDx.